Comparative Pharmacology
Head-to-head clinical analysis: GENOSYL versus NEOMYCIN SULFATE POLYMYXIN B SULFATE HYDROCORTISONE.
Head-to-head clinical analysis: GENOSYL versus NEOMYCIN SULFATE POLYMYXIN B SULFATE HYDROCORTISONE.
GENOSYL vs NEOMYCIN SULFATE-POLYMYXIN B SULFATE-HYDROCORTISONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Genosyl (sodium phenylbutyrate) is a prodrug that is metabolized to phenylacetate, which conjugates with glutamine via acetylation to form phenylacetylglutamine. This alternative pathway facilitates waste nitrogen excretion in patients with urea cycle disorders.
Neomycin sulfate is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibiting protein synthesis in susceptible bacteria. Polymyxin B sulfate is a polypeptide antibiotic that disrupts bacterial cell membrane integrity by interacting with phospholipids. Hydrocortisone is a corticosteroid that suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and modulating immune cell activity.
5 mg orally once daily for 14 days, then 2.5 mg orally once daily thereafter.
Otic: Instill 3-5 drops into the affected ear(s) 3-4 times daily; for acute otitis externa, a wick may be used initially.
None Documented
None Documented
Terminal half-life 3.5 hours; clinically relevant for dosing every 6-8 hours in renal impairment.
Neomycin: 2-3 hours (renal impairment: up to 12-24 hours). Polymyxin B: 4.5-6 hours (prolonged in renal failure). Hydrocortisone: 1.5-2 hours.
Renal: 85% unchanged; biliary/fecal: 15% as metabolites.
Neomycin is excreted primarily unchanged in feces (97%) after oral administration; absorbed fraction is renally excreted (30-50%). Polymyxin B is renally excreted (60%) with some biliary excretion. Hydrocortisone is metabolized hepatically and excreted renally as conjugates.
Category C
Category A/B
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic